Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated July 24, 2024, titled "Alembic Pharmaceuticals receives USFDA Final Approval for Fluphenazine Hydrochloride Tablets USP, 1 mg, 2.5 mg, 5 mg, and 10 mg".
Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated July 24, 2024, titled "Alembic Pharmaceuticals receives USFDA Final Approval for Fluphenazine Hydrochloride Tablets USP, 1 mg, 2.5 mg, 5 mg, and 10 mg".